Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland

IMPORTANCE: Biologics account for a substantial proportion of health care expenditures. Their costs have been projected to reach US $452 billion in global spending by 2022. Given recent expiration of patent protection of biologics, a shift toward greater follow-on competition among biosimilars would...

Descripción completa

Detalles Bibliográficos
Autores principales: Carl, David L., Laube, Yannic, Serra-Burriel, Miquel, Naci, Huseyin, Ludwig, Wolf-Dieter, Vokinger, Kerstin N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719051/
https://www.ncbi.nlm.nih.gov/pubmed/36459139
http://dx.doi.org/10.1001/jamanetworkopen.2022.44670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719051/
https://www.ncbi.nlm.nih.gov/pubmed/36459139
http://dx.doi.org/10.1001/jamanetworkopen.2022.44670

Ejemplares similares